Company research
XORTX Therapeutics Inc.
CIK 1729214Updated Sep 26, 2026
SecuritiesXRTX · TSXV · equityXRTX · NASDAQ · equity
Historical securities (1)
XRTXF · OTC · equity · closed Sep 22, 2021XRTX price & chart
Loading TradingView…
TSXV:XRTX on TradingView ↗About the company
XORTX Therapeutics is a late clinical-stage biotechnology company focused on identifying, developing and potentially commercializing therapies to treat diseases modulated by aberrant purine and uric acid metabolism in indications such as gout, autosomal dominant polycystic kidney disease (“ADPKD”) an orphan (rare) disease and larger, more prevalent type 2 diabetic nephropathy (“T2DN”) as well as acute kidney injury (“AKI”) associated with respiratory virus infection. In addition, XORTX has expanded interest to include anti-fibrotic medicine in kidney disease.
In the news
XORTX Appoints New Director ↗
XORTX Meets Nasdaq Continued Listing Requirements ↗
XORTX Confirms Effective Date of Share Consolidation ↗
Recent filings
Show 5 more recent filings
Financials
FY 2021 · CADcash flow · annual statements
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Cash flows from operating activities: | ||
| Profit or LossCAD | -1,652,282Source | -1,284,602Source |
| Additional Financial Items | ||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableCAD | -37,188Source | — |
| AdjustmentsForSharebasedPaymentsCAD | 499,158Source | 293,443Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsCAD | -325,741Source | 1,201Source |
| GeneralAndAdministrativeExpenseCAD | 176,099Source | 9,516Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesCAD | 39,809Source | 14,350Source |
income statement · annual statements
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Additional Financial Items | ||
| AdministrativeExpenseCAD | 4,198Source | — |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossCAD | 6,119,000Source | — |
| DepreciationAndAmortisationExpenseCAD | 17,882Source | 20,439Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesCAD | 499,158Source | 293,443Source |
| GeneralAndAdministrativeExpenseCAD | 176,099Source | 9,516Source |
| PostemploymentBenefitExpenseDefinedContributionPlansCAD | 380,000Source | 192,000Source |
| ProfessionalFeesExpenseCAD | 272,943Source | 162,580Source |
| ProfitLossBeforeTaxCAD | -3,649,523Source | -1,395,993Source |
| ResearchAndDevelopmentExpenseCAD | 853,124Source | 277,455Source |
Offerings
Registration 333-290512
- Gross proceeds
- 5000000.0
- Net proceeds
- 4800000.0
- Deal price
- 1.88
- Shares
- 2659574
- Offering price
- $1.88
- Ticker
- XRTX